Health Monitor Liechtenstein: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Liechtenstein.

Press releases published on March 24, 2026

Mar. 24, 2026

Nature Translational Psychiatry Study Reveals Distinct Functional Neuronal Signatures in Patient-Derived Brain Organoids with Itay&Beyond’s Neurotech Platform

Indeterminate GlobeNewswire

Mar. 24, 2026

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant

Indeterminate GlobeNewswire

Mar. 24, 2026

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Indeterminate GlobeNewswire

Mar. 24, 2026

Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis

Indeterminate GlobeNewswire

Mar. 24, 2026

Press release: Availability of the Q1 2026 aide-mémoire

Indeterminate GlobeNewswire

Mar. 24, 2026

Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »

Indeterminate GlobeNewswire

Mar. 24, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Indeterminate GlobeNewswire

Mar. 24, 2026

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Indeterminate GlobeNewswire

Mar. 24, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse  

Indeterminate GlobeNewswire

Mar. 24, 2026

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Indeterminate GlobeNewswire

Mar. 24, 2026

Phonak AI-Powered Hearing Aids Recognized with 2026 Artificial Intelligence Excellence Awards

Indeterminate GlobeNewswire

Mar. 24, 2026

Nghiên cứu lâm sàng cung cấp bằng chứng cho việc sử dụng Lacprodan® IF-3070 của Arla Foods Ingredients trong sữa công thức dành cho trẻ sơ sinh

Indeterminate GlobeNewswire

Mar. 24, 2026

Studi Klinis Menunjukkan Bukti untuk Penggunaan Lacprodan® IF-3070 dari Arla Foods Ingredients dalam Susu Formula Bayi

Indeterminate GlobeNewswire

Mar. 24, 2026

Kajian Klinikal Menunjukkan Bukti Keberkesanan Penggunaan Lacprodan® IF-3070 Oleh Arla Foods Ingredients dalam Formula bayi

Indeterminate GlobeNewswire

Mar. 24, 2026

การศึกษาวิจัยทางคลินิกให้หลักฐานยืนยันสำหรับการใช้ Lacprodan® IF-3070 ของ Arla Foods Ingredients ในนมผงสำหรับทารก

Indeterminate GlobeNewswire

Mar. 24, 2026

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

Indeterminate GlobeNewswire